OCA treatment (6 weeks) was well-tolerated and increased insulin sensitivity and reduced markers of liver inflammation and fibrosis in diabetic and non-alcoholic fatty liver disease (NAFLD) patients. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.